Filing Flows › Orchestra BioMed Holdings (OBIO) › Q2 2025
Orchestra BioMed Holdings (OBIO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Orchestra BioMed Holdings (OBIO) reported revenue of $836K for the second quarter 2025 (Q2 2025), +7% from a year earlier and -4% from the quarter before.
Orchestra BioMed Holdings, Q2 2025: revenue $836K (+8% year over year), net loss $19.4M, operating cash flow −$15.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $836K | -4% | +7% |
| Operating profit | −$19.3M | — | — |
| Net earnings | −$19.4M | — | — |
| Operating cash flow | −$15.5M | — | — |
What changed
Revenue was $836K in Q2 2025, up 7% year over year and down 4% from the previous quarter. Partnership revenue was the largest line at 80% of revenue. Partnership revenue added $39K year over year (up 6%), 67% of the total change.
Operating costs exceeded revenue by $19.3M, an operating margin of -2311.8%. Total costs grew 14% against revenue growth of 7%. The fastest-growing cost line was Research & development (+25%). The quarter ended with a net loss of $19.4M, wider than the previous quarter's $18.8M loss.
Operating cash flow was −$15.5M. Non-cash charges added back $81K of depreciation and $3.2M of share-based compensation. Capital expenditures of $34K exceeded it, leaving free cash flow of −$15.6M.
Questions
What was Orchestra BioMed Holdings' revenue in the second quarter 2025?
Orchestra BioMed Holdings (OBIO) reported revenue of $836K for the second quarter 2025 (Q2 2025), +7% from a year earlier and -4% from the quarter before.